Buitrón-Santiago N, Arteaga-Ortiz L, Rosas-López A, Aguayo Á, López-Karpovitch X, Crespo-Solís E

Language: Spanish
References: 31
Page: 100-108
PDF size: 82.42 Kb.

ABSTRACT

Introduction. Acute myeloid leukemia (AML) comprises a group of diseases with different biologic characteristics; despite knowledge improvements, these are not reflected in long term survival. Objective. To describe characteristics of adults with AML in a hospital of Mexico City, their treatment response, complications and to evaluate survival related factors. Material and methods. Cohort study. Between January 2003 and July 2008, patients with AML diagnosis were included (except promyelocitic). Treatment protocols used: 3+7, high doses of cytarabine and autologous bone marrow transplant as consolidation therapy. Results. 53 patients were included. Median age: 44 years (15-79). At diagnosis: tumor lysis syndrome in 4/ 53 (7.5%), 3/51 (5.9%) with altered liver function test and hyperleukocytosis in 8/53 (15.1%). 46 patients had available cytogenetic and this was successful in 28/46 (60.8%), 12/28 (42.8%) had adverse cytogenetic; 16/28 (57.1%) intermediate risk and none was favorable. There were 2 losses during follow up, 7 patients did not receive chemotherapy with curative intent and 1 died at diagnosis. 43 patients received 3+7, 13.9% died during aplasia, complete remission was achieved in 27/43 (62.7%) and 10/43 (23.2%) were refractory to treatment. A second induction attempt was required in 39.5% (17/43). Median disease free survival (DFS) was 491days (366-615), with a median follow up of 993 days (105-1744). The median overall survival (OS) was 531 days (312-749). Aplasia related mortality decreased (p = 0.09) between the actual cohort (13.9%) and the historical cohort (37%). Conclusions. Long term survival in AML patients remains poor despite improvements in diagnosis, classification, and treatment. In our institution, it is required to improve induction protocols and cytogenetic analysis in order to adequately choose the group of patients that could be benefit from stem cell transplant.

REFERENCES

1. Stone R. Acute myeloid leukemia. Hematology 2004: 98- 117.

2. Tallman M, Gilliland G, Rowe J. Drug therapy for acute myeloid leukemia. Blood 2005; 106: 1154-63.

3. Jaffe E, Stein H, Vardiman JW. (2001) WHO: Classification of Tumours. Tumours of Haematopoietic and Lymhoid Tissue. IARC Press, Lyon.

4. Yates JW, Wallace HR, Ellison RR, et al. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep 1973; 57: 485.

5. Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorrubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 77: 1666-74.

6. Vogler W, Velez-Garcia E, Weiner R, et al. Phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol 1992; 10: 1103-11.

7. Buchner T, Hiddemann W, Wörmann B, et al. Double induction strategy for acute myeloid leukemia: the effect of highdose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999; 93(12): 4116-24.

8. Lobato-Mendizabal E, Ruiz-Arguelles G, Gomez-Almaguer D, et al. Tratamiento a largo plazo y factores pronósticos en leucemia aguda mieloblástica del adulto. Experiencia del grupo INNSZ (Puebla-Monterrey-México). Rev Invest Clin 1991; 43: 215-22.

9. Bennett J. Proposals for the classification of the acute leukemias. Br J Haematol 1976; 33: 451-8.

10. Omura G, Vogler R, Lefante J, et al. Treatment of acute myelogenous leukemia: influence of three induction regimens and maintenance with chemotherapy of BCG immunotherapy. Cancer 1982; 49: 1530-6.

11. Mayer R, Davis R, Schiffer C, et al. intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331: 896-903.

12. Byrd J, Mrozek K, Dodge R, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse and overall survival in adult patients with de novo acute myeloid leukemia: results from cancer and leukemia Group B (CALGB 8461). Blood 2002; 100: 4325-36.

13. Ugarte A, Villasis A, Hernández ME, Crespo E, Ruiz GM, Ponce- De-León, et al. Utilidad de la profilaxis con fluoroquinolonas durante la neutropenia grave inducida por quimioterapia en pacientes con leucemia aguda, en un hospital de referencia de la ciudad de México con alta prevalencia de resistencia a fluoroquinolonas. Rev Invest Clin 2006; 58: 547-54.

14. Cheson BD, Cassilth PA, Head DR, Schiffer, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990; 8: 813-19.

15. Miller K. Clinical manifestations of acute leukemia. In: Hoffman Hematology, Basic Principles and Practice. 5th. Ed. Churchill and Livingstone; 2008.

16. Pillay Y, McLellan G, Davison G, et al. CD7 expression does not predict for poor outcome in acute myeloblastic leukemia. Blood 1995; 85: 3357-9.

17. Griffin J, Davis R, Nelson D, et al. Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia. Blood 1986; 68: 1232-41.

18. Byrd J, Mrozek K, Dodge R. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from cancer and leukemia Group B (CALGB 8461). Blood 2002; 100: 4325-36.

19. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 Trial. Blood 1998; 92: 2322-33.

20. Slovak M, Kopecky K, Cassileth P, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/ Eastern Cooperative Oncology Group study. Blood 2000; 96: 4075-83.

21. Jeha S, Giles F. Chapter 10: Acute myeloid leukemia in American Society of Hematology Self Assesment Program. 2007.

22. Infante-Sierra H, Crespo-Solis E, López-Karpovitch X, et al. Reporte preliminar: evaluación del esquema 7+3 en leucemia mieloide aguda y tasa de mortalidad temprana en una cohorte retrospectiva versus cohorte prospectiva. Rev Fac Med UNAM 2008; 51(4): 150-5.

23. Estey E, Smith TL, Keating MJ, et al. Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. Leukemia 1989; 3(4): 257-63.

24. Moore J, Dodge R, Amrein P, et al. Granulocyte-Colony Stimulating Factor (Filgrastim) Accelerates Granulocyte Recovery After Intensive Postremission Chemotherapy for Acute Myeloid Leukemia With Aziridinyl Benzoquinone and Mitoxantrone: Cancer and Leukemia Group B Study 9022. Blood 1997; 89: 780-8.

25. Khalidi HS, Medeiros LJ, Chang KL, et al. The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities. Am J Clin Pathol 1999; 109(2): 211-20.

26. Jiao B, Wu CF, Liang Y, et al. AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2. Leukemia 2009, 21 de mayo (publicación electrónica antes de la impresa).

27. Zittoun R, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332: 217-23.

28. Harousseau JL, Cahn J, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood 1997; 90: 2978-86.

29. Cassileth P, Harrington D, Apperlbaum F, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649-56.

30. Ferrant A, Labopin M, Frassoni F, et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation Study. Blood 1997; 90: 2931-8.

31. Löwenberg B. Acute myeloid leukemia: the challenge of capturing disease variety. Hematology 2008: 1-11.